Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway.
about
(125)I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinomaThe neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma.Downregulated connexin32 promotes EMT through the Wnt/β-catenin pathway by targeting Snail expression in hepatocellular carcinoma.The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway.Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinomaDown-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells.Salvianolic acid A reverses the paclitaxel resistance and inhibits the migration and invasion abilities of human breast cancer cells by inactivating transgelin 2.MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.Synergistic reversal effect of epithelial-to-mesenchymal transition by miR-223 inhibitor and genistein in gemcitabine-resistant pancreatic cancer cells.MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer.miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells.Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer.Volatile oil from Saussurea lappa exerts antitumor efficacy by inhibiting epithelial growth factor receptor tyrosine kinase-mediated signaling pathway in hepatocellular carcinoma.PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway.Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells.The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer.Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Republished: Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape.MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer.NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells.The molecular mechanisms of chemoresistance in cancers.Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC.Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells.Fabrication and Cytotoxicity of Gemcitabine-Functionalized Magnetite Nanoparticles.PHD-finger domain protein 5A functions as a novel oncoprotein in lung adenocarcinoma.Hippo pathway contributes to cisplatin resistant-induced EMT in nasopharyngeal carcinoma cells.How Tumor Cells Choose Between Epithelial-Mesenchymal Transition and Autophagy to Resist Stress-Therapeutic Implications.PDGF/PDGFR effects in osteosarcoma and the "add-on" strategy
P2860
Q24658608-ABF458B4-D467-47ED-B4DA-931F6EA7BB04Q33566593-DB10C225-E006-4698-B29E-0B92843102E3Q33699418-A5C2FD44-D0EC-4494-93DE-72F22CBF8073Q34483637-97BF5456-7C5C-49BC-8C35-CA4570139080Q34786434-825C2AC2-ECDC-45E9-BD03-4027910FEF01Q35176428-6FCB6AF1-2194-4AB7-97B4-8A6058261F7EQ35537834-AD28FE8D-D9BD-4CAD-97BE-79B0E799A687Q35550226-ED0A3475-D273-4AC5-AF50-168278C4E537Q35740131-CD41099A-CAA2-4A07-8DCB-5D5DDA4DD5F1Q36212778-6C737A4A-A47D-40D9-A67B-F1F0D6FE201DQ36508613-7A933CBA-6EAA-427B-9AE2-1FFEBD684C48Q37077423-BA8C6123-36C0-4568-AEB3-B5BE690B6830Q37269340-E5DF0570-E8AB-4589-BE19-6981A1F372D6Q37611689-F35A10F9-2458-4929-BD11-CE1233095D97Q37632152-D48B78D3-EA90-47FA-A451-E27CF6717E1EQ37694839-7AA69DBD-2770-41B7-95F6-213AB6D47C84Q37706090-E6D9A5F7-70F3-4C63-ADFE-40D01AB72446Q37711659-14155DBA-FE23-4F7F-A2F2-036A3086C0F5Q38206587-ECE88CBC-D6F6-4E52-A767-4488EA4667E2Q38241160-021D6A4E-98C6-4A43-BF3C-54799FD5D6BFQ38481540-9538EF02-A578-469C-9E3C-ED82C6626FF6Q38543837-3E782EFF-5911-4815-8C33-233F9490DA55Q38811818-A2EE7FE0-C8C3-4C57-A186-AB360536CADCQ38853517-0B24B948-FBB2-4702-967E-EBAC4916F743Q41709101-E3045627-171E-47A1-9D91-7481F14CDDB0Q47119773-C20CA5C9-6261-4EEA-A4E3-28819F3AD9DAQ47883740-FF0D3F5C-56A2-49C0-A173-4F465CE1BFE4Q47978647-D76AFB03-6D0B-43B4-8A99-16896ABBFA74Q52642387-CAD21A55-6BEB-4F3A-9F7F-A6F1B303382EQ52760977-2C94DC05-270A-45BE-9643-1E53DC94C7DDQ55713309-715629F7-5087-4AEF-99CA-69AE16D611E7Q58803894-26AAE9AC-72BE-4CC1-AF79-C7202D299E86
P2860
Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Chemoresistance to gemcitabine ...... activation of PDGF-D pathway.
@en
Chemoresistance to gemcitabine ...... activation of PDGF-D pathway.
@nl
type
label
Chemoresistance to gemcitabine ...... activation of PDGF-D pathway.
@en
Chemoresistance to gemcitabine ...... activation of PDGF-D pathway.
@nl
prefLabel
Chemoresistance to gemcitabine ...... activation of PDGF-D pathway.
@en
Chemoresistance to gemcitabine ...... activation of PDGF-D pathway.
@nl
P2093
P2860
P356
P1433
P1476
Chemoresistance to gemcitabine ...... activation of PDGF-D pathway.
@en
P2093
Changjie Chen
Fazlul H Sarkar
Qingling Yang
Sulian Chen
Yueyue Hou
Yuqing Chen
P2860
P304
P356
10.18632/ONCOTARGET.1471
P407
P577
2013-11-01T00:00:00Z